2021
DOI: 10.1101/2021.09.15.21263613
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

COVID-19 vaccine effectiveness against hospitalizations and ICU admissions in the Netherlands, April- August 2021

Abstract: The objective of this study was to estimate vaccine effectiveness (VE) against COVID-19 hospitalization and ICU admission, per period according to dominating SARS-CoV-2 variant (Alpha and Delta), per vaccine, and per time since vaccination. To this end, data from the national COVID-19 vaccination register was added to the national register of COVID-19 hospitalizations. For the study period 4 April- 29 August 2021, 15,571 hospitalized people with COVID-19 were included in the analysis, of whom 887 (5.7%) were f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

5
29
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
3
1

Relationship

3
5

Authors

Journals

citations
Cited by 26 publications
(35 citation statements)
references
References 7 publications
5
29
1
Order By: Relevance
“…During the delta variant period in the Netherlands, overall VE against hospitalization was 91% for Comirnaty, 96% for Spikevax, 88% for Vaxzevria and 82% for Janssen. 1 Antibody data from our study mirrored these trends which supports the notion that antibody binding and neutralization correlate with vaccine efficacy. 12 However, the relative difference in VE estimates is smaller than in antibody levels, indicating that antibody levels alone do not constitute immune protection, as expected.…”
Section: Discussionsupporting
confidence: 82%
See 1 more Smart Citation
“…During the delta variant period in the Netherlands, overall VE against hospitalization was 91% for Comirnaty, 96% for Spikevax, 88% for Vaxzevria and 82% for Janssen. 1 Antibody data from our study mirrored these trends which supports the notion that antibody binding and neutralization correlate with vaccine efficacy. 12 However, the relative difference in VE estimates is smaller than in antibody levels, indicating that antibody levels alone do not constitute immune protection, as expected.…”
Section: Discussionsupporting
confidence: 82%
“…High vaccine effectiveness (VE) data related to the prevention of hospitalization due to have been reported up to 20 weeks after vaccination. 1,2 In the Netherlands, four vaccines have been included in the national vaccination program and are either mRNA-based (Comirnaty and Spikevax) or vector-based (Vaxzevria and Janssen). mRNA-based vaccines use lipid nanoparticles to deliver Spike-encoding mRNA and vector-based vaccines use adenovirus to deliver Spike-encoding DNA to induce expression of the Spike protein by human cells.…”
Section: Introductionmentioning
confidence: 99%
“…An OR for Delta of 1.9 implicates a reduction of vaccine effectiveness from 90% to 80%, which has been shown in the UK 3,27 . Current literature still shows high vaccine effectiveness of 90-95% against severe COVID-19 for the Delta variant 7,17 , which is reassuring. However, note that with very high vaccine effectiveness, a difference of a factor 1.5-2.0 between two variants could go unnoticed, as it would only mean a decrease of effectiveness of 95 to 92%.…”
Section: Discussionmentioning
confidence: 89%
“…Janssen COVID-19 vaccine (Ad26.COV2.S, Janssen) has been used most in the 50-59 years age group and young adults (3.4% of all administered doses) 12 . Vaccination has proven to be highly effective against COVID-19, especially against hospitalization and death and reduces the secondary attack rate within households 7,[13][14][15][16][17] .…”
Section: Introductionmentioning
confidence: 99%
“…In field trials, several vaccines proved less efficacious against VOCs, in particular the Beta [13][14][15][16][17][18][19][20] . In fact, the Oxford/AstraZeneca vaccine was virtually ineffective in preventing symptomatic COVID-19 in South-Africa, where the Beta variant dominated during the trial 21 .…”
Section: Introductionmentioning
confidence: 99%